PEG Peptide

PEG Peptide

Antibody drug conjugates (ADCs) consist of a desirable monoclonal antibody, a highly potent cytotoxic payload and an appropriate linker. As an innovative therapeutic approach for targeted oncology treatments, ADC has emerged as a very powerful anticancer therapy with more than eight drugs approved by the FDA.

ADC linkers play key roles in determining the pharmacokinetic properties, therapeutic index and the overall success of the ADC. A well-designed linker helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers play critical roles in an ADCs’ stability during preparation, storage and systemic circulation. Two kinds of ADC linkers are used in current ADC drugs: cleavable linkers and non-cleavable linkers

BroadPharm offers a broad range of ADC linkers and payload to further empower pharmaceutical ADC drug discovery & development.

Featured products: PEG peptide, Val-Cit, Val-Cit-PAB, Val-Cit-PAB-PNP, PEG linkers, DBCO, BCN, Azide, Tetrazine, TCO, MMAE, DM1, DM4 and other payload.

BroadPharm also offers customer-oriented ADC linker synthesis and services to our customers worldwide.

Product Number
Product Name
Structure
M.W.
Purity
Val-Cit
274.3
98%
 
Val-Cit-PAB-OH
379.5
95%
 
Fmoc-Val-Cit-PAB-OH
601.7
95%
 
Fmoc-Val-Cit-PAB-PNP
766.8
95%
 
Boc-Val-Cit
374.4
95%
 
Boc-Val-Cit-PAB
479.6
95%
 
Boc-Val-Cit-PAB-PNB
644.7
95%
 
MC (C5)-Val-Cit
452.5
98%
 
MC-Val-Cit-PAB-OH
572.7
96%
 
MC-Val-Cit-PAB-PNP
737.8
95%
 
SPDP-Val-Cit-PAB-OH
576.7
98%
 
SPDP-Val-Cit-PAB-PNP
741.8
98%
 
Mal-PEG2-Val-Cit-PAB-OH
618.7
95%
Mal-PEG4-Val-Cit-PAB-OH
706.8
96%
 
Mal-PEG1-Val-Cit-PAB-PNP
739.7
96%
Mal-PEG4-Val-Cit-PAB-PNP
871.9
97%
 
Mal-amido-PEG2-Val-Cit-PAB-OH
689.8
98%
 
Mal-amido-PEG2-Val-Cit-PAB-PNP
854.9
98%
 
Azido-PEG3-Val-Cit-PAB-OH
608.7
96%
Azido-PEG4-Val-Cit-PAB-OH
652.8
96%
 
Azido-PEG3-Val-Cit-PAB-PNP
773.8
95%
 
BCN-PEG3-Val-Cit
653.8
98%
 
BCN-PEG3-VC-PFP Ester
819.8
96%
 
 
Mal-amido-PEG8-val-gly-PAB-OH
854.0
98%
 
 
Fmoc-PEG4-Ala-Ala-Asn-PAB
849.0
95%
 
Azido-PEG5-Ala-Ala-Asn-PAB
696.8
95%
 
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB
1047.2
96%
 
Azido-PEG4-Ala-Ala-Asn(Trt)-PAB
895.0
96%
 
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP
1212.3
95%
 
 
Auristatin E
732.0
95%
Val-Cit-PAB-MMAE
1123.5
95%
MC-Val-Cit-PAB-MMAE
1316.7
98%
Fmoc-Val-Cit-PAB-MMAE
1345.7
98%
 
Amino-PEG4-Val-Cit-PAB-MMAE
1370.7
98%
 
Azido-PEG4-Val-Cit-PAB-MMAE
1396.7
98%
 
endo-BCN-PEG4-Val-Cit-PAB-MMAE
1547.0
98%
 
Mal-PEG8-Val-Cit-PAB-MMAE
1627.0
 
MC-MMAF
925.2
98%
MMAF-methyl ester
746.0
 
Monomethyl Dolastatin 10
771.1
95%
 
Maytansinoid
565.1
98%
Maytansinoid AP-3
635.2
95%
 
 
Cabazitaxel
836.0
95%
 
Paclitaxel
853.9
95%
7-O-(Amino-PEG4)- paclitaxel
1101.2
98%
7-O-(Cbz-N-amido-PEG4)- paclitaxel
1235.4
98%
 
N-(Iodoacetamido)-Doxorubicin
711.5
 
N-(4-((2,5-dioxo-2H-pyrrol-1(5H)-yl)methyl)cyclohexane)-Doxorubicin
762.8
98%
 
MC-Val-Cit-Doxorubicin
1142.2
98%